Trump signals tariff plans, Fed chair candidates, China deal progress
Investing.com - DAM Capital has initiated coverage on OneSource Specialty Pharma Ltd (ONESOURC:IN) with a Buy rating and a price target of INR2,529.00.
The research firm describes OneSource as a "differentiated multi-platform specialty CDMO company" with capabilities across Drug-Device Combinations, Soft Gelatin Capsules, Sterile Injectables, and Biologics.
DAM Capital highlights OneSource’s first-mover advantage in the Drug-Device Combinations space, supported by aggressive capacity expansion, a diversified client base, and high-quality execution, positioning it to benefit from multi-year volume growth in generic GLP-1 injectables globally.
The firm projects strong growth for OneSource with a 33% compound annual growth rate (CAGR) in revenue, 42% CAGR in EBITDA, and 60% CAGR in adjusted profit after tax over FY25-28E, with approximately 40% adjusted return on capital employed.
DAM Capital’s INR2,529 price target represents a multiple of 30 times FY28E earnings per share, supported by near-term earnings visibility, strong cash flow generation, and potential profit share from a U.S. generic Wegovy launch expected in 2032.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.